Results of a new national survey conducted by the Alliance for Safe Biologic Medicines (ASBM) shows that Canadian physicians support the use of distinguishable names for biologic therapies, including biosimilars,
Results of a new national survey conducted by the Alliance for Safe Biologic Medicines (ASBM) show that Canadian physicians support the use of distinguishable names for biologic therapies, including biosimilars, and that these physicians are open to using biosimilars for non-medical reasons so long as they retain control over the decision to switch a patient’s treatment.
The results of the survey were recently presented at the Drug Information Association Annual Canadian meeting in Ottawa by ASBM's past chairman, Harry Gewanter, MD.
"Distinguishable non-proprietary naming for all biologic medicines is important for the appropriate use of originator biologics and biosimilars, as well as pharmacovigilance," said Gewanter in a statement. "Further, Canadian physicians believe it is critical that the physician-patient relationship remains central when deciding which treatments their patients will utilize."
The survey found the following:
"The results of our survey provide important insight and evidence to regulators and policymakers on the perspectives of Canadian prescribers of biologic medicines," said Michael Reilly, executive director of ASBM. "For originator biologics and biosimilars to be used successfully, decision makers should rely on the input and opinions of those who prescribe them, working collaboratively to develop policies that minimize potential safety or efficacy issues."
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.